Veltuzumab is a second-generation humanized anti-CD20 antibody now in clinical testing, which works very similarly to rituximab, except that lower doses and shorter infusion times can be used, Stein says. Both of the drugs tested in this study, milatuzumab and veltuzumab, were developed by Immunomedics, Inc. Stein and her colleagues were funded through grants from the National Cancer Institute and the New Jersey Department of Health and Senior Services
These preclinical studies suggest benefit in testing the combination in patients, Stein says. We believe that combination antibody therapy, just as combination chemotherapy, will be the future for antibody-based immunotherapy, she said.
Neoadjuvant clinical trials for biomarker discovery: An old idea to solve a new problem: Abstract A229.
With the recent approval of four new agents and more coming through the drug development pipeline, treatment of advanced common kidney cancer has become a multiple choice decision of late − but one without a definitive answer. Physicians say they have no rational way to decide which drugs or drug combinations would work best for patients with renal cell carcinoma, especially those whose cancer has recurred and spread.
Now, researchers at the University of North Carolina at Chapel Hill are adapting the idea of neoadjuvant therapy − treating cancer before surgery − to renal cell carcinoma. Their intent is to use a short course of treatment to evaluate the performance of the new d
|Contact: Greg Lester|
American Association for Cancer Research